Neu 120

Drug Profile

Neu 120

Alternative Names: Neu-120; NMDA receptor modulators - Neurim Pharmaceuticals; NMDAR modulators - Neurim Pharmaceuticals

Latest Information Update: 03 Nov 2014

Price : $50

At a glance

  • Originator Neurim Pharmaceuticals
  • Class Antiparkinsonians
  • Mechanism of Action Glycogen synthase kinase 3 beta inhibitors; Monoamine oxidase B inhibitors; NMDA receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Drug-induced dyskinesia

Most Recent Events

  • 03 Nov 2014 Phase-I development is ongoing in Israel
  • 08 Oct 2014 Neurim Pharmaceuticals terminates a phase I/II trial in Parkinson's disease (Adjunctive treatment)/Drug-induced dyskinesia in Israel (NCT00607451)
  • 31 Mar 2008 Phase-I/II clinical trials in Drug-induced dyskinesia in Israel (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top